Biomarcadores de las Enfermedades Cardíacas
BIOMARCS
University of Hull
Kingston upon Hull, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Hull (3)
2024
-
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Hypertension Research
-
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Heart, Vol. 110, Núm. 19, pp. 1180-1187
2022
-
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331